Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
Manage episode 337560103 series 103624
Creato da PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education, autore scoperto da Player FM e dalla nostra community - Il copyright è detenuto dall'editore, non da Player FM, e l'audio viene riprodotto direttamente dal suo server. Clicca sul pulsante Iscriviti per rimanere aggiornato su Player FM, o incolla l'URL del feed in un altra app per i podcast.
Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.